Experience for Women With Ovarian Cancer After Multiple Lines of PARP Inhibitor Therapy
More data are needed regarding the efficacy and safety of administering multiple lines of PARP inhibitor therapy, according to researchers.
Society of Gynecologic Oncology (SGO)
Simultaneous Sequencing of Paired Germline and Somatic Specimens Enhanced Clinical Care in Ovarian Cancer
Simultaneous molecular characterization of paired germline and tumor specimens may gain importance as more targeted therapies become available.
ARIEL3: Rucaparib Maintenance Across Age Groups in Advanced Ovarian Cancer
Women aged 75 and older with advanced ovarian cancer enrolled in the phase 3 ARIEL3 trial were less likely to have deleterious germline or somatic BRCA mutations.
SGO Annual Meeting on Women’s Cancer: What to Expect
Preview key themes and trends that will be presented during the Society of Gynecologic Oncology (SGO)’s 50th Annual Meeting on Women’s Cancer.
Pembrolizumab: Cost-Effective for Recurrent, MSI-H Endometrial Cancer
Per-cycle, PLD cost $2509, bevacizumab cost $7585, and pembrolizumab cost $9026.
Uterine Re-Curettage May Not Affect Required Chemotherapy Courses in GTN
After the initial year of follow-up, 2 patients in the standard arm and 1 patient in the re-curettage arm had relapsed.
Bevacizumab Plus Chemotherapy Prolongs PFS in Endometrial Cancer With p53 Null Status
p53 mutational status may be a viable strategy upon which to base the course of therapy.
Adjuvant Chemotherapy Non-Inferior to Chemoradiotherapy in Cervical Cancer
There were no significant differences in patterns of recurrence in the chemotherapy vs CCRT groups.
One-Quarter of Patients With Gynecologic Cancer Cannot Afford Medical Care
Nearly half of patients were denied insurance coverage for a recommended treatment.
Trastuzumab With Carboplatin, Paclitaxel Improves PFS in Uterine Serous Carcinoma
Toxicity was similar in both arms.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in SGO 2018
Loading... 
Loading...